411 related articles for article (PubMed ID: 30423407)
21. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
22. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
23. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Itsumi M; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(9):959-69. PubMed ID: 24740858
[TBL] [Abstract][Full Text] [Related]
25. Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer.
Thaper D; Vahid S; Kaur R; Kumar S; Nouruzi S; Bishop JL; Johansson M; Zoubeidi A
Sci Rep; 2018 Nov; 8(1):17307. PubMed ID: 30470788
[TBL] [Abstract][Full Text] [Related]
26. Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy.
Jiang W; Chen J; Gong C; Wang Y; Gao Y; Yuan Y
J Nanobiotechnology; 2020 Mar; 18(1):50. PubMed ID: 32188463
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of glucocorticoid receptor-mediated glucose transporter 4 in enzalutamide-resistant prostate cancer.
Hoshi S; Meguro S; Imai H; Matsuoka Y; Yoshida Y; Onagi A; Tanji R; Honda-Takinami R; Matsuoka K; Koguchi T; Hata J; Sato Y; Akaihata H; Kataoka M; Ogawa S; Kojima Y
Cancer Sci; 2021 May; 112(5):1899-1910. PubMed ID: 33619826
[TBL] [Abstract][Full Text] [Related]
29. Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer.
Zhao J; Zhao Y; Wang L; Zhang J; Karnes RJ; Kohli M; Wang G; Huang H
Oncotarget; 2016 Jun; 7(25):38551-38565. PubMed ID: 27221037
[TBL] [Abstract][Full Text] [Related]
30. miR-5089-5p suppresses castration-resistant prostate cancer resistance to enzalutamide and metastasis via miR-5089-5p/SPINK1/ MAPK/MMP9 signaling.
Wang ZC; Li Y; Wang KL; Wang L; You BS; Zhao DF; Liu ZQ; Fang RZ; Wang JQ; Zhang W; Zhang JM; Xu WH
Aging (Albany NY); 2020 Jul; 12(14):14418-14433. PubMed ID: 32694237
[TBL] [Abstract][Full Text] [Related]
31. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
32. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
Pilling AB; Hwang C
Prostate; 2019 Aug; 79(11):1347-1359. PubMed ID: 31228231
[TBL] [Abstract][Full Text] [Related]
33. LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling.
Luo J; Wang K; Yeh S; Sun Y; Liang L; Xiao Y; Xu W; Niu Y; Cheng L; Maity SN; Jiang R; Chang C
Nat Commun; 2019 Jun; 10(1):2571. PubMed ID: 31189930
[TBL] [Abstract][Full Text] [Related]
34. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
[TBL] [Abstract][Full Text] [Related]
35. Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide.
Hong Z; Xiang Z; Zhang P; Wu Q; Xu C; Wang X; Shi G; Hong Z; Wu D
Clin Transl Med; 2021 Jul; 11(7):e495. PubMed ID: 34323404
[TBL] [Abstract][Full Text] [Related]
36. The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer.
Liu B; Sun Y; Tang M; Liang C; Huang CP; Niu Y; Wang Z; Chang C
Cell Death Dis; 2020 Sep; 11(9):807. PubMed ID: 32978369
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of
Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X
Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003
[TBL] [Abstract][Full Text] [Related]
39. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
Khurana N; Talwar S; Chandra PK; Sharma P; Abdel-Mageed AB; Mondal D; Sikka SC
Int J Oncol; 2016 Oct; 49(4):1609-19. PubMed ID: 27499349
[TBL] [Abstract][Full Text] [Related]
40. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]